<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223963</url>
  </required_header>
  <id_info>
    <org_study_id>31GB0902</org_study_id>
    <nct_id>NCT01223963</nct_id>
  </id_info>
  <brief_title>Macrolane Retrospective Study</brief_title>
  <official_title>A Multi-center Retrospective Chart Review of Medical Records on the Use of Macrolane Volume Restoration Factor for Breast Enhancement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, multicenter chart review of medical records on the use of Macrolane
      for female breast enhancement.

      The primary objective is to evaluate the safety profile of Macrolane Volume Restoration
      Factor 20 and Macrolane Volume Restoration Factor 30 when used for female breast enhancement
      in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>A retrospective chart review to evaluate the safety profile of Macrolane Volume Restoration Factor 20 and Volume Restoration Factor 30 when used for female breast enhancement in clinical practice</measure>
    <time_frame>01may2008 - 31dec2009</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">93</enrollment>
  <condition>Women Who Have Had Breast Enhancement With Macrolane VRF</condition>
  <arm_group>
    <arm_group_label>Macrolane</arm_group_label>
    <description>Women that have had breast enhancement with Macrolane Volume Restoration Factor.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women that have had breast enhancement in clinics in Sweden (and UK).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females treated with Macrolane Volume Restoration Factor 20 and/or Volume Restoration
             Factor 30 for breast enhancement.

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Subjects that have actively asked not to be contacted by the clinic

          -  Subjects that have participated or participates in clinical studies with Macrolane
             for breast enhancement
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hedén, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademikliniken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stureplanskliniken</name>
      <address>
        <city>Göteborg</city>
        <zip>411 05</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Malmö</city>
        <zip>217 53</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stureplanskliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>111 44</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>115 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 22, 2012</lastchanged_date>
  <firstreceived_date>October 15, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macrolane</keyword>
  <keyword>Retrospective</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
